Top Page
Radiopharm Theranostics Limited
(Sydney:RAD)
Radiopharm Theranostics Limited (RAD) vs. iShares MSCI Australia ETF (EWA)
Radiopharm Theranostics Limited Business Overview & Revenue Model
Radiopharm Theranostics Limited Financial Statement Overview
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 12.35M | 13.40M | 299.23K | 292.36K | 8.83K | 0.00 |
| Gross Profit | 21.33M | 9.81M | -21.31M | -3.00M | -2.97M | 0.00 |
| EBITDA | -43.11M | -31.65M | -45.38M | -37.11M | -18.04M | -484.75K |
| Net Income | -44.94M | -36.70M | -47.95M | -34.61M | -30.34M | -485.19K |
Balance Sheet | ||||||
| Total Assets | 91.17M | 86.48M | 72.04M | 74.95M | 83.38M | 33.44K |
| Cash, Cash Equivalents and Short-Term Investments | 34.52M | 29.12M | 18.58M | 11.70M | 26.98M | 27.09K |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 59.00K |
| Total Liabilities | 41.23M | 43.61M | 44.68M | 29.37M | 20.42M | 158.14K |
| Stockholders Equity | 51.78M | 44.79M | 28.12M | 44.38M | 62.96M | -124.70K |
Cash Flow | ||||||
| Free Cash Flow | -37.10M | -36.65M | -22.98M | -24.73M | -38.25M | -32.91K |
| Operating Cash Flow | -37.10M | -36.65M | -22.98M | -23.20M | -9.91M | -32.91K |
| Investing Cash Flow | -6.54M | 1.77M | 0.00 | -1.53M | -28.37M | 0.00 |
| Financing Cash Flow | 42.26M | 45.43M | 29.88M | 9.22M | 65.11M | 60.00K |
Radiopharm Theranostics Limited Technical Analysis
Radiopharm Theranostics Limited Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
55 Neutral | AU$81.52M | -1.51 | -100.67% | ― | 1114.27% | 85.66% | |
52 Neutral | AU$156.16M | -4.74 | ― | ― | ― | 0.66% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | AU$71.50M | -6.80 | -49.72% | ― | ― | 10.78% | |
45 Neutral | AU$6.63M | ― | -469.35% | ― | ― | 46.28% | |
41 Neutral | AU$29.03M | -28.33 | -30.33% | ― | ― | ― | |
41 Neutral | AU$56.16M | -5.40 | -71.87% | ― | 7.65% | -19.13% |
Radiopharm Theranostics Limited Corporate Events
Radiopharm Theranostics reported a 44% increase in its half-year loss to A$26.97 million for the six months ended 31 December 2025, with net tangible assets per share declining to 0.14 cents from 0.18 cents a year earlier. The company did not declare any dividends, while its interim financial statements received an unmodified review opinion from its independent auditor.
During the period, Radiopharm Theranostics increased its stake in Radiopharm Ventures, LLC, a joint venture with The University of Texas M.D. Anderson Cancer Center, from 75% to 87.5%. The higher ownership in this oncology-focused venture underscores the company’s strategic commitment to expanding its theranostic platform despite widening losses and the absence of shareholder distributions.
The most recent analyst rating on (AU:RAD) stock is a Hold with a A$0.02 price target. To see the full list of analyst forecasts on Radiopharm Theranostics Limited stock, see the AU:RAD Stock Forecast page.
Radiopharm Theranostics reported its half-year financial results to 31 December 2025 alongside business updates, highlighting strong clinical progress across its oncology radiopharmaceutical pipeline and a solid cash position of approximately $34.52 million, which is expected to fund operations into 2027 through key clinical and regulatory milestones. Interim Phase 2b data for its lead imaging candidate RAD 101 in patients with recurrent brain metastases showed 92% MRI concordance, reinforcing earlier findings and supporting plans for a potential Phase 3 registrational study if results are confirmed, while additional Phase 1 data for therapeutic candidates RAD 202 and RAD 204 in advanced solid tumors are anticipated in mid-2026, underscoring the company’s focus on advancing multiple programs and enhancing its competitive positioning in radiotheranostics.
The most recent analyst rating on (AU:RAD) stock is a Hold with a A$0.02 price target. To see the full list of analyst forecasts on Radiopharm Theranostics Limited stock, see the AU:RAD Stock Forecast page.
Radiopharm Theranostics Limited has notified the ASX that 400,000 options with an exercise price of A$0.60, expiring on 22 December 2025 and trading under the code RADAH, have lapsed unexercised. The expiry slightly reduces the company’s pool of potential dilutive securities but does not involve any new capital raising or share issuance, suggesting a minor housekeeping adjustment to its capital structure rather than a shift in strategy or operations for existing shareholders.
The most recent analyst rating on (AU:RAD) stock is a Buy with a A$0.06 price target. To see the full list of analyst forecasts on Radiopharm Theranostics Limited stock, see the AU:RAD Stock Forecast page.
Radiopharm Theranostics has disclosed a change in the interests of director Paul Hopper, who was issued 18,142,000 unlisted options as approved by shareholders at the company’s Annual General Meeting on 20 November 2025. Following this non-cash issuance, Hopper’s direct holdings increased to 53,900,000 shares and 53,642,000 options, with his total direct and indirect option interests rising to 62,659,518, signalling continued alignment of the director’s incentives with shareholder interests and the company’s long-term strategic objectives.
The most recent analyst rating on (AU:RAD) stock is a Buy with a A$0.06 price target. To see the full list of analyst forecasts on Radiopharm Theranostics Limited stock, see the AU:RAD Stock Forecast page.
Radiopharm Theranostics has disclosed a change in director Ian Turner’s interests in the company’s securities, following shareholder approval at the 20 November 2025 Annual General Meeting. Turner has been issued 6,814,000 additional unlisted options on a non-cash basis pursuant to a shareholder-approved resolution, increasing his total holding to 25,802,350 options (24,981,928 held directly and 820,422 indirectly), while his shareholding remains unchanged at 9,255,292 shares. The issuance reflects ongoing equity-based remuneration and further aligns the director’s incentives with shareholder interests, but does not involve any on-market transactions or changes to contractual interests.
The most recent analyst rating on (AU:RAD) stock is a Buy with a A$0.06 price target. To see the full list of analyst forecasts on Radiopharm Theranostics Limited stock, see the AU:RAD Stock Forecast page.
Radiopharm Theranostics Limited has notified the market of the issue of 99,294,000 unquoted options under its employee incentive scheme, which are not intended to be quoted on the ASX and have various expiry dates and exercise prices. The issuance of these unquoted equity securities is designed to support the company’s remuneration and retention strategy by aligning employee incentives with shareholder interests, potentially leading to future dilution if the options are exercised, but also signaling a focus on long-term value creation and staff engagement.
The most recent analyst rating on (AU:RAD) stock is a Buy with a A$0.06 price target. To see the full list of analyst forecasts on Radiopharm Theranostics Limited stock, see the AU:RAD Stock Forecast page.
Radiopharm Theranostics Limited has announced the proposed issuance of 39,644,767 fully paid ordinary shares through a placement expected to occur on December 31, 2027. This move demonstrates the company’s commitment to further strengthening its capital base, potentially facilitating expansion, innovation in radiopharmaceutical development, and improved positioning within the industry as it continues to pursue technological advancement in cancer treatment and diagnostics.
The most recent analyst rating on (AU:RAD) stock is a Buy with a A$0.05 price target. To see the full list of analyst forecasts on Radiopharm Theranostics Limited stock, see the AU:RAD Stock Forecast page.
Radiopharm Theranostics Limited has announced the establishment of an At-the-Market (ATM) equity facility in the U.S., enabling the sale of American Depositary Shares (ADSs) to raise capital for product development and corporate needs. The ATM facility, which permits flexible, incremental fundraising based on prevailing market conditions, is a strategic move aiming to leverage U.S. capital markets, potentially raising up to $22.4 million initially with a wider $50 million ceiling over three years, enhancing the company’s financial flexibility in line with market trends.
The most recent analyst rating on (AU:RAD) stock is a Buy with a A$0.05 price target. To see the full list of analyst forecasts on Radiopharm Theranostics Limited stock, see the AU:RAD Stock Forecast page.
Radiopharm Theranostics Limited recently announced an inadvertent non-compliance with ASX Listing Rule 7.1 due to an oversights regarding the inclusion of milestone shares in its capacity calculation. This led to the company exceeding its placement capacity in October 2025, impacting the validity of certain placement shares for ratification. In response, the company intends to bolster its governance measures, increase awareness among officers, and engage external advisors to ensure full compliance and maintain best practices moving forward.
The most recent analyst rating on (AU:RAD) stock is a Buy with a A$0.05 price target. To see the full list of analyst forecasts on Radiopharm Theranostics Limited stock, see the AU:RAD Stock Forecast page.
Radiopharm Theranostics announced that their Phase 2b trial of RAD 101 in brain metastases achieved its primary endpoint, with 92% of patients showing concordance with MRI imaging. This interim data bolsters confidence in the trial’s success and supports the potential initiation of a pivotal study by the end of 2026. The U.S. market opportunity for RAD 101 is estimated at over $500 million annually, positioning it as a top imaging agent. The trial has reached 50% patient enrollment and has received FDA Fast Track Designation, highlighting its significance in differentiating recurrent disease from treatment effects in brain metastases.
The most recent analyst rating on (AU:RAD) stock is a Buy with a A$0.05 price target. To see the full list of analyst forecasts on Radiopharm Theranostics Limited stock, see the AU:RAD Stock Forecast page.
Radiopharm Theranostics Limited has announced that Paul Hopper has ceased to be a substantial holder in the company as of December 9, 2025. This change was due to a dilution from a placement, which affects the voting securities of the company. The announcement may impact the company’s shareholder structure and could influence its market dynamics.
The most recent analyst rating on (AU:RAD) stock is a Buy with a A$0.05 price target. To see the full list of analyst forecasts on Radiopharm Theranostics Limited stock, see the AU:RAD Stock Forecast page.
Radiopharm Theranostics Limited has issued 750,960,477 ordinary fully paid shares without disclosure under Part 6D.2 of the Corporations Act. The company has complied with relevant provisions of the Corporations Act and confirms there is no excluded information required to be disclosed, indicating a strategic move to strengthen its financial position and potentially expand its market presence.
The most recent analyst rating on (AU:RAD) stock is a Buy with a A$0.05 price target. To see the full list of analyst forecasts on Radiopharm Theranostics Limited stock, see the AU:RAD Stock Forecast page.
Radiopharm Theranostics Limited has announced the application for quotation of new securities on the Australian Securities Exchange (ASX). The company plans to quote 750,960,477 ordinary fully paid shares and 1,166,666,667 options expiring in 2027, which could potentially strengthen its financial position and support its strategic growth initiatives in the radiopharmaceutical sector.
The most recent analyst rating on (AU:RAD) stock is a Buy with a A$0.05 price target. To see the full list of analyst forecasts on Radiopharm Theranostics Limited stock, see the AU:RAD Stock Forecast page.
Radiopharm Theranostics Limited has announced a new application for the quotation of securities on the Australian Securities Exchange (ASX). The company plans to issue 12,599,991 options expiring on October 31, 2027, at an exercise price of $0.039. This move is part of a securities purchase plan, which could potentially strengthen the company’s financial position and support its ongoing projects in the radiopharmaceutical sector.
The most recent analyst rating on (AU:RAD) stock is a Buy with a A$0.05 price target. To see the full list of analyst forecasts on Radiopharm Theranostics Limited stock, see the AU:RAD Stock Forecast page.
Radiopharm Theranostics Limited has released a holdings report indicating that a significant portion of its shares, 99.89%, is held by large stakeholders, with CITICORP NOMINEES PTY LIMITED being the largest shareholder at 36.96%. This concentration of ownership suggests a strong backing by major investors, potentially impacting the company’s strategic decisions and market influence.
The most recent analyst rating on (AU:RAD) stock is a Buy with a A$0.05 price target. To see the full list of analyst forecasts on Radiopharm Theranostics Limited stock, see the AU:RAD Stock Forecast page.
Radiopharm Theranostics Limited announced that all resolutions considered at their recent General Meeting were successfully passed by poll. These resolutions included the ratification of prior share placements and approvals for issuing additional shares and options, which are expected to support the company’s financial strategies and enhance its market position.
The most recent analyst rating on (AU:RAD) stock is a Buy with a A$0.05 price target. To see the full list of analyst forecasts on Radiopharm Theranostics Limited stock, see the AU:RAD Stock Forecast page.
Radiopharm Theranostics Limited has successfully completed its share purchase plan (SPP), raising A$0.4 million, which contributes to a total of A$35.4 million raised alongside a placement announced earlier. The SPP offered new shares at A$0.03 each, and a total of 12,599,991 ordinary shares are scheduled to be issued. The issuance of SPP Attaching Options, with an exercise price of A$0.039 and expiring in October 2027, is also planned, reflecting the company’s strategic efforts to strengthen its financial position and support its operations.
The most recent analyst rating on (AU:RAD) stock is a Buy with a A$0.05 price target. To see the full list of analyst forecasts on Radiopharm Theranostics Limited stock, see the AU:RAD Stock Forecast page.
JPMorgan Chase & Co. and its affiliates have ceased to be substantial holders in Radiopharm Theranostics Ltd, a company involved in the development of radiopharmaceutical products. The change in substantial holding is due to transactions involving the rehypothecation of client securities and the purchase and sale of securities by J.P. Morgan Securities Australia Limited and J.P. Morgan Securities LLC. This development may impact the company’s shareholder structure and could influence its market positioning and stakeholder interests.
The most recent analyst rating on (AU:RAD) stock is a Buy with a A$0.05 price target. To see the full list of analyst forecasts on Radiopharm Theranostics Limited stock, see the AU:RAD Stock Forecast page.